{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:33:19Z","timestamp":1789907599726,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030831","name":"Novartis Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jcyt.2025.04.067","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:43:44Z","timestamp":1744944224000},"page":"938-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Koji","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-5480","authenticated-orcid":false,"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9973","authenticated-orcid":false,"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-5670","authenticated-orcid":false,"given":"Hidefumi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-4978","authenticated-orcid":false,"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-7768","authenticated-orcid":false,"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jcyt.2025.04.067_bib0001","article-title":"CAR-T cell therapy for hematological malignancies: History, status, and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0002","unstructured":"Kymriah. Prescribing information. Novartis. 2024. Available from: https:\/\/www.fda.gov\/media\/107296\/download. Accessed on April 31, 2024."},{"key":"10.1016\/j.jcyt.2025.04.067_bib0003","unstructured":"PMDA. Review Reports: Regenerative Medical Products. 2024. Available from https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/0004.html. Accessed on June 27, 2024."},{"key":"10.1016\/j.jcyt.2025.04.067_bib0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0005","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.18609\/cgti.2018.105","article-title":"Management of \u201cout of specification\u201d commercial autologous CAR-T cell products","volume":"4","author":"Bersenev","year":"2018","journal-title":"Cell Gene Ther Insights"},{"issue":"suppl 1","key":"10.1016\/j.jcyt.2025.04.067_bib0006","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2021-144897","article-title":"Optimizing commercial manufacturing of tisagenlecleucel in the US: a 4-year experiential journey","volume":"138","author":"Rodrigues","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.067_bib0007","first-page":"100","article-title":"Commercial manufacturing experience of tisagenlecleucel in Europe: >3 years journey","volume":"57","author":"Rodrigues","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.reth.2025.02.001","article-title":"Optimizing commercial manufacturing of tisagenlecleucel for patients in Japan: a 4-year experiential Journey","volume":"28","author":"Iwamoto","year":"2025","journal-title":"Regen. Ther."},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.067_bib0009","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2019002258","article-title":"Maude S.L., et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit?","volume":"134","author":"Chong","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.067_bib0010","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukaemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jcyt.2025.04.067_bib0011","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1080\/10428194.2022.2123232","article-title":"Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel","volume":"63","author":"Fried","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.jcyt.2025.04.067_bib0012","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2021012392","article-title":"Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukaemia","volume":"138","author":"Rossoff","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.067_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41409-024-02205-6","article-title":"Out of specification tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma","volume":"59","author":"Philippis","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0014","unstructured":"FDA draft guidance document. Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers. Available from: https:\/\/www.fda.gov\/media\/162793\/download. Accessed on 22 October 2024."},{"key":"10.1016\/j.jcyt.2025.04.067_bib0015","unstructured":"NCT04094311. ClinicalTrial.gov. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04094311. Accessed on March 27, 2024."},{"issue":"2","key":"10.1016\/j.jcyt.2025.04.067_bib0016","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2025.04.067_bib0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.jcyt.2025.04.067_bib0018","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0019","unstructured":"National comprehensive cancer network (NCCN) guidelines. Acute lymphoblastic leukemia. 2024 (v2). Available from https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1410. Accessed on September 28, 2024."},{"issue":"24","key":"10.1016\/j.jcyt.2025.04.067_bib0020","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.067_bib0021","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2025.04.067_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcyt.2025.04.067_bib0023","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.04.067_bib0024","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcyt.2025.04.067_bib0025","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.04.067_bib0026","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","article-title":"Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan","volume":"28","author":"Goto","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.04.067_bib0027","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.04.067_bib0028","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:10:24Z","timestamp":1762546224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925006851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1465324925006851"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.067","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}